Contravisory Investment Management Inc. increased its position in DaVita Inc. (NYSE:DVA – Free Report) by 1.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 6,082 shares of the company’s stock after buying an additional 73 shares during the period. Contravisory Investment Management Inc.’s holdings in DaVita were worth $910,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also added to or reduced their stakes in DVA. FMR LLC raised its holdings in DaVita by 659.9% in the 3rd quarter. FMR LLC now owns 177,406 shares of the company’s stock worth $29,082,000 after purchasing an additional 154,061 shares during the period. Glenmede Trust Co. NA lifted its stake in DaVita by 731.6% in the 3rd quarter. Glenmede Trust Co. NA now owns 123,269 shares of the company’s stock worth $20,207,000 after purchasing an additional 108,446 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in DaVita by 17.8% during the third quarter. JPMorgan Chase & Co. now owns 609,076 shares of the company’s stock worth $99,846,000 after buying an additional 92,014 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of DaVita in the second quarter valued at about $9,615,000. Finally, KBC Group NV grew its stake in shares of DaVita by 27.3% in the 3rd quarter. KBC Group NV now owns 313,519 shares of the company’s stock valued at $51,395,000 after buying an additional 67,250 shares during the period. Hedge funds and other institutional investors own 90.12% of the company’s stock.
DaVita Stock Performance
Shares of DaVita stock opened at $162.32 on Thursday. The stock has a market capitalization of $13.31 billion, a price-to-earnings ratio of 17.51, a PEG ratio of 0.75 and a beta of 0.92. The firm’s fifty day simple moving average is $156.49 and its 200-day simple moving average is $152.43. The company has a debt-to-equity ratio of 15.78, a current ratio of 1.37 and a quick ratio of 1.33. DaVita Inc. has a 12 month low of $103.40 and a 12 month high of $169.51.
Analyst Ratings Changes
DVA has been the subject of a number of research analyst reports. Truist Financial raised their target price on DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a report on Monday, October 7th. Barclays boosted their price target on shares of DaVita from $150.00 to $164.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $161.80.
Check Out Our Latest Stock Report on DVA
DaVita Profile
DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Featured Stories
- Five stocks we like better than DaVita
- 3 Grocery Stocks That Are Proving They Are Still Essential
- Vertex’s Pain Drug: Big Pharma’s Next Major Success?
- There Are Different Types of Stock To Invest In
- D-Wave’s Stock Springs Back in the Quantum Computing Race
- What is a Special Dividend?
- 2 Top ETFs to Profit From the Natural Gas Price Surge
Want to see what other hedge funds are holding DVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DaVita Inc. (NYSE:DVA – Free Report).
Receive News & Ratings for DaVita Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DaVita and related companies with MarketBeat.com's FREE daily email newsletter.